Citrus Bergamot: The Research, and Who's Behind It

By Erin Rose · Updated July 19, 2026 · Methodology

Educational overview — not medical advice. Citrus bergamot is grapefruit-family and carries a real statin/CYP3A4 drug-interaction caution; talk to your clinician before combining it with a statin or other prescription medication. This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.

As an Amazon Associate we earn from qualifying purchases. On best citrus bergamot, products are ranked by disclosed polyphenol standardization first, cost second — not by commissions.

Start here

What citrus bergamot is, and why the evidence is structurally lopsided

Citrus bergamot (Citrus bergamia) is a citrus fruit grown almost exclusively in a small region of Calabria, Italy, and marketed as a supplement, mostly for lipid health, in a standardized extract called BPF (bergamot polyphenolic fraction). The evidence base behind that marketing is real, but it has a structural problem worth naming plainly: most of the positive human trials trace back to a small cluster of Italian research groups. The Mollace group at Magna Graecia University of Catanzaro developed BPF and holds commercial and institutional interest in it — their 2011 foundational paper is the origin point for the entire BPF commercial category. Several trials from the Cicero/Fogacci group in Bologna were funded by nutraceutical manufacturers Meda-Mylan, Scharper, or Esserre Pharma. That doesn't make the findings false — but it means the largest, most eye-catching effect sizes (the largest reported LDL changes) need to be read next to evidence from people with no stake in the outcome, and that independent evidence tells a more modest story.

Four threads, read honestly

First, the foundational human data is not RCT-grade: Mollace's 2011 paper reported changes in lipid and glucose measures in 237 patients given BPF for 30 days, but the abstract doesn't describe randomization or blinding — it reads as an open cohort, not a placebo-controlled trial, and it's the paper the entire category built on. Second, the statin-combination trial was small and open-label: Gliozzi 2013 (n=77, 30 days) is called "placebo-controlled" but was open-label, not double-blind, and comes from the Mollace/Catanzaro group. Third, the single largest, most dramatic result has no control group at all: Toth 2015 (n=80, 6 months) reported changes in LDL and carotid intima-media thickness — but it's a single-arm before/after study with no placebo comparison, so regression to the mean, diet changes, or observer effects can't be ruled out, and a 6-month cIMT reduction that large is a result that needs independent replication before it's taken at face value. Fourth, and most important to weigh against the first three: the one clearly independent systematic review is far more cautious. Lamiquiz-Moneo 2020 (a Spanish lipid unit with no bergamot-industry tie) screened 442 studies down to 12 that met eligibility, found 75% reported a change in lipid measures but concluded the studies "had heterogeneous designs and scientific quality of studies was quite limited." That's the most rigorous single verdict in this evidence base, and it belongs at the top of any honest summary, not buried under the more dramatic industry-linked numbers.

The one null result, and why it matters

Not every bergamot trial found a benefit. Bruno 2017 gave a lower 500mg/day BPF dose to psychiatric outpatients on antipsychotic medication for 60 days and found it did not change clinical or metabolic parameters — only 9 of 24 completers had any LDL change at all. This trial comes from an independent group (University of Messina psychiatry department, no bergamot-industry tie) and its own authors suggest the population or dose may simply need adjustment — it's a genuinely useful negative counterweight, not a discredited study to wave away. A separate, independent Polish public-health review (Kłosiewicz-Latoszek 2021) put it plainly: the review reported that for other nutraceuticals the evidence was more favorable, "however, the evidence of benefits of berberine and bergamot is not so conclusive," and "the opinion of experts on berberine and bergamot is ambiguous."

The safety note that matters most

Citrus bergamia is botanically related to grapefruit, and like grapefruit, it contains furanocoumarins capable of inhibiting intestinal CYP3A4 — the same enzyme pathway that metabolizes many statins (simvastatin, lovastatin, atorvastatin) and numerous other prescription drugs. Some commercial BPF extracts are marketed as reduced-furanocoumarin or furanocoumarin-free, but that's a manufacturer processing claim, not something independently verified in the evidence reviewed for this page. One small supervised trial combined bergamot with a statin at a single amount; that is not a safety clearance. Anyone on a statin or other CYP3A4-metabolized medication should talk to a clinician or pharmacist before adding a bergamot supplement, the same caution given for grapefruit. Long-term (multi-year) human safety data does not exist — no trial in this evidence base ran longer than 6 months. Pregnant or breastfeeding people, and anyone with existing liver or kidney disease, should get a clinician's input before use.

Frequently asked questions

Sources

Related guides

• CoQ10
• Garlic for blood pressure — another cardiometabolic supplement with a mixed-quality European trial base
• Berberine for blood sugar